Good thinking Pete. My post...
Talking about some of the longs staying away until fruition really.
Yes, each indication would be better split amongst the best BP's in the area concerned.
I would also consider that Leo feels the same.
Quote:Cabel as well. I'm too hyper. Every flinch of ipix by even a penny, green or red... I just look at the end game.
The tally stands at a VERY EXCELLENT potential for Brilacidin partnership. Already looking at phase 3 MAJOR trials. Meeting with the FDA along with BP's through their CDA's. Great potential there.
Kevetrin already got the answers they need to complete the oral formulation that has been the foal for YEARS. Very much looking forward to seeing a short phase 2c into a major phase 3 trial, that may include some I know (in which case I would also have to vanish from posting on this ).
And prurisol data from a trial designed rigorously with BP that cold post over the next few weeks or even sooner.
Yeah, I'm in.
Talking about some of the longs staying away until fruition really.
Yes, each indication would be better split amongst the best BP's in the area concerned.
I would also consider that Leo feels the same.
Quote:I have had a change of heart recently as to how I would like to see the company proceed down the line. I use to think partnering out P and continuing to build the value of K and B in further trials was the route to go, but I have now changed my view in thinking for the betterment of mankind it would be far better for IPIX to partner out all 3 platforms with a healthy royalty program for any and all future indications.
My reasoning is that each of our drugs has such widespread uses that it is going to take massive amounts of trials to cover the entire spectrum of their respective abilities. That is why I don't want to see just one BP get all platforms. Give them to separate BPs and let each make a fortune by getting them online as quickly as possible.
We all have heard how the scope of B applications has hardly been scratched, we knew that K was suppose to possibly be able to work on 50% of cancers and possibly more in combination forms, and now we are hearing how Prurisol has widespread applications in autoimmune diseases and cancer, namely IL-20 and breast cancer. As time goes on, we keep hearing more and more how each of these drugs are blossoming with additional areas to investigate.
I hope the recent changes at IPIX reflect mgt's belief that they also believe the correct path is akin to what I have described above. It all makes sense to me that it could be the route they have chosen.
Would love to hear other views as to forward expectations.
